Monitor for future Form 4 filings to see if any new inducement grants are made under this expanded plan. The increased share reserve provides flexibility for hiring, but does not represent immediate dilution.
Price Chart
Executive Summary
Xenon Pharmaceuticals amended and restated its 2025 Inducement Equity Incentive Plan to increase the share reserve from 900,000 to 1,175,000 common shares, to be used exclusively for hiring inducements. This filing is routine and does not involve any new equity grants or executive appointments.
Key Facts
- Company amended and restated its 2025 Inducement Equity Incentive Plan
- Increased share reserve from 900,000 to 1,175,000 common shares
- New shares to be used exclusively for inducement grants to new hires or rehires
- No shareholder approval required under Nasdaq Listing Rule 5635(c)(4)
- Filing is administrative and does not involve any new equity grants
Financial Impact
Potential future dilution of up to 1,175,000 shares, but no immediate financial impact as no new grants were issued
Risk Factors
- Potential future dilution if the full share reserve is utilized
- No immediate risk as no new grants were issued in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152834 |
| Document: xene-20260407.htm | 0001193125-26-152834 |
| Document: 0001193125-26-152834-index-headers.html | 0001193125-26-152834 |
| Document: 0001193125-26-152834-index.html | 0001193125-26-152834 |
| Document: 0001193125-26-152834.txt | 0001193125-26-152834 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 2, 2026 13w ago | Press Release | $60.96 $64.19 | ▲ +5.30% | ▲ +5.71% | $38.02 (−37.63%) |
Jun 5, 2026 17w ago | 144 | $51.21 $60.54 | ▲ +18.22% | ▲ +16.59% | $38.02 (−25.76%) |
Jun 3, 2026 17w ago | 8-K | $52.99 $60.96 | ▲ +15.04% | ▲ +16.41% | $38.02 (−28.25%) |
May 7, 2026 21w ago | Press Release | $56.44 $51.73 | ▼ −8.35% | ▼ −8.37% | $38.02 (−32.64%) |
Apr 22, 2026 23w ago | DEFA14A | $55.41 $54.68 | ▼ −1.32% | ▼ −5.95% | $38.02 (−31.38%) |
Apr 19, 2026 23w ago | Press Release | $57.09 $53.71 | ▼ −5.92% | ▼ −10.12% | $38.02 (−33.40%) |
Apr 15, 2026 24w ago | Press Release | $58.88 $55.00 | ▲ +6.59% | ▲ +12.63% | $38.02 (+35.43%) |
Apr 13, 2026 24w ago | 8-K | $59.35 $55.78 | ▼ −6.02% | ▼ −12.31% | $38.02 (−35.94%) |
Apr 7, 2026 25w ago | Press Release | $57.65 $57.40 | ▲ +0.43% | ▲ +10.21% | $38.02 (+34.05%) |
Mar 13, 2026 29w ago | Insider Cluster | $55.23 $58.60 | ▼ −6.10% | ▼ −2.51% | $38.02 (+31.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access